Malignant Solid Neoplasm — Trials

Malignant Solid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 429
Recruiting: 209
Ph III recruiting: 10
Growth YoY: +2.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (101)

clinicaltrialsPublishedShowing 51–100 of 189 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05554367	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	active not recruiting	Phase 2	199	National Cancer Institute (NCI)NIH	2	Aug 21, 2026	clinicaltrials
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA)	recruiting	Phase 1 / Phase 2	138	Mayo ClinicOTHER	1	Aug 20, 2026